KERX, they have enough cash to take the company into mid-2013. Adam Feurstein's article kind of put a damper on things. He fails to mention the possibility for decreased usage of Epo agents for those on Zerenex in his analysis. If the Phase III trial shows a reduced cost to maintain hemoglobin levels then it would be winner no matter the threat from generics.
News 
Market Data 
Discover 
